Abstract
INTRODUCTION
We conducted a rapid systematic review of minimal clinically important differences (MCIDs) for Alzheimer’s disease (AD) trial endpoints.
METHODS
Two reviewers searched EMBASE, MEDLINE, and PubMed from inception to June 4, 2023.
RESULTS
Ten articles were retrieved. For mild cognitive impairment (MCI), a change of +2 to +3 points on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), +1 points on the Clinical Dementia Rating scale sum of boxes (CDR-SB), −5 points on the integrated Alzheimer’s Disease Rating Scale (iADRS), or −1 to −2 points on the Mini-Mental State Examination (MMSE) was considered meaningful. For patients with mild AD, a change of +3 on the ADAS-Cog, +2 points on CDR-SB, −9 points on the iADRS, or −2 points on the MMSE was considered meaningful. For patients with moderate to severe AD, a change of +2 points on the CDR-SB or a change of −1.4 to −3 points on the MMSE was considered meaningful.
CONCLUSION
This review identified previously published MCIDs for AD trial endpoints. Input from patients and caregivers will be needed to derive more meaningful endpoints and thresholds.
Highlights
This systematic rapid review identified thresholds for minimal clinically important differences (MCIDs) for recently used Alzheimer’s disease (AD) trial endpoints: Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), Clinical Dementia Rating scale sum of boxes (CDR-SB), integrated Alzheimer’s Disease Rating Scale (iADRS), Mini-Mental State Examination (MMSE).
MCIDs were higher for more severe stages of AD.
Average treatment effects in recent trials of anti-amyloid disease modifying monoclonal antibodies are lower than previously published MCIDs.
In future trials of disease modifying treatments for AD, the proportion of participants in each treatment group that experienced a clinically meaningful decline could be reported.
More work is needed to incorporate the values and preferences of patients and care partners in deriving MCIDs.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Ryan T. Muir,
Michael D. Hill,
Sandra E. Black,
Eric E. Smith | April 2, 2024